Literature DB >> 19429731

Prostate-specific antigen testing among the elderly in community-based family medicine practices.

Shawna V Hudson1, Pamela Ohman-Strickland, Jeanne M Ferrante, Grace Lu-Yao, A John Orzano, Benjamin F Crabtree.   

Abstract

BACKGROUND: Controversy surrounds prostate-specific antigen (PSA) testing for prostate cancer screening, especially among elderly men aged 75 and older. This study examines whether patient age results in differential use of PSA testing and if organizational attributes such as communication, stress, decision making, and practice history of change predict PSA testing among men aged 75 and older.
METHODS: Data came from chart audits of 1149 men > or =50 years old who were patients of 46 family medicine practices participating in 2 northeastern practice-based research networks. Surveys administered to clinicians and staff in each practice provide practice-level data. A stratified Cochran-Mantel-Haenszel test was applied to examine whether PSA testing decreased with age. Hierarchical logistic regression analyses determined characteristics associated with PSA testing for men > or =75 years old.
RESULTS: Comparable rates for annual PSA testing of 77.2% for men aged 50 to 74 years and 74.6% for men > or =75 years old were reported. The Cochran-Mantel-Haenszel test indicated no significant change in trend. Hierarchical models suggest that practice communication is the only organizational attribute that influences PSA testing for men 75 years of age or older (odds ratio, 5.04; P = .022). Practices with higher communication scores (eg, promoted constructive work relationships and a team atmosphere between staff and clinicians) screened men aged 75 and older at lower rates than others.
CONCLUSIONS: Elderly men in community settings receive PSA testing at rates comparable to their younger counterparts even though major clinical practice guidelines discourage the practice for this population. Intraoffice practice interventions that target PSA testing to the most appropriate populations and focus on communication (both within the office and with patients) are needed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19429731      PMCID: PMC2756417          DOI: 10.3122/jabfm.2009.03.080136

Source DB:  PubMed          Journal:  J Am Board Fam Med        ISSN: 1557-2625            Impact factor:   2.657


  56 in total

1.  Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancer.

Authors:  P Carroll; C Coley; D McLeod; P Schellhammer; G Sweat; J Wasson; A Zietman; I Thompson
Journal:  Urology       Date:  2001-02       Impact factor: 2.649

2.  Tailoring tobacco counseling to the competing demands in the clinical encounter.

Authors:  C R Jaén; H McIlvain; L Pol; R L Phillips; S Flocke; B F Crabtree
Journal:  J Fam Pract       Date:  2001-10       Impact factor: 0.493

3.  Screening for prostate cancer: recommendation and rationale.

Authors: 
Journal:  Ann Intern Med       Date:  2002-12-03       Impact factor: 25.391

4.  Understanding and appreciating overdiagnosis in the PSA era.

Authors:  Siu-Long Yao; Grace Lu-Yao
Journal:  J Natl Cancer Inst       Date:  2002-07-03       Impact factor: 13.506

5.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2008-08-05       Impact factor: 25.391

6.  Prostate cancer screening practices and beliefs.

Authors:  J D Voss; J M Schectman
Journal:  J Gen Intern Med       Date:  2001-12       Impact factor: 5.128

7.  Factors influencing use of the prostate-specific antigen screening test in primary care.

Authors:  W P Moran; S J Cohen; J S Preisser; J L Wofford; B J Shelton; M W McClatchey
Journal:  Am J Manag Care       Date:  2000-03       Impact factor: 2.229

8.  Understanding practice from the ground up.

Authors:  B F Crabtree; W L Miller; K C Stange
Journal:  J Fam Pract       Date:  2001-10       Impact factor: 0.493

9.  A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer.

Authors:  Lars Holmberg; Anna Bill-Axelson; Fred Helgesen; Jaakko O Salo; Per Folmerz; Michael Häggman; Swen-Olof Andersson; Anders Spångberg; Christer Busch; Steg Nordling; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson; Bo Johan Norlén
Journal:  N Engl J Med       Date:  2002-09-12       Impact factor: 91.245

Review 10.  Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback.

Authors:  David F Ransohoff; Mary McNaughton Collins; Floyd J Fowler
Journal:  Am J Med       Date:  2002-12-01       Impact factor: 4.965

View more
  6 in total

1.  Remaining Life Expectancy Measurement and PSA Screening of Older Men.

Authors:  Ashwin A Kotwal; Supriya G Mohile; William Dale
Journal:  J Geriatr Oncol       Date:  2012-07-01       Impact factor: 3.599

2.  Older age does not impact perioperative complications after robot-assisted radical prostatectomy.

Authors:  Leah Y Nakamura; Rafael N Nunez; Paul E Andrews; Robert G Ferrigni; Mitchell R Humphreys; Scott K Swanson; Christopher E Wolter; Erik P Castle
Journal:  J Robot Surg       Date:  2011-02-05

3.  The impact of PSA testing frequency on prostate cancer incidence and treatment in older men.

Authors:  Y-H Shao; P C Albertsen; W Shih; C B Roberts; G L Lu-Yao
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-06-28       Impact factor: 5.554

4.  Medical center characteristics associated with PSA screening in elderly veterans with limited life expectancy.

Authors:  Cynthia So; Katharine A Kirby; Kala Mehta; Richard M Hoffman; Adam A Powell; Stephen J Freedland; Brenda Sirovich; Elizabeth M Yano; Louise C Walter
Journal:  J Gen Intern Med       Date:  2011-12-17       Impact factor: 5.128

5.  Breast, colorectal and prostate cancer screening for cancer survivors and non-cancer patients in community practices.

Authors:  Shawna V Hudson; Karissa A Hahn; Pamela Ohman-Strickland; Regina S Cunningham; Suzanne M Miller; Benjamin F Crabtree
Journal:  J Gen Intern Med       Date:  2009-11       Impact factor: 5.128

6.  Use of the prostate-specific antigen test among men aged 75 years or older in the United States: 2006 Behavioral Risk Factor Surveillance System.

Authors:  Jun Li; Guixiang Zhao; Lori A Pollack; Judith Lee Smith; Djenaba A Joseph
Journal:  Prev Chronic Dis       Date:  2010-06-15       Impact factor: 2.830

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.